Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2140178 | Leukemia Research | 2006 | 7 Pages |
Abstract
For refractory and early relapsed AML, this prospective phase II clinical trial evaluated a salvage chemotherapy regimen, which was consisted of continuous infusion intermediate-dose cytarabine (1 g/m2/day, 24 h i.v. infusion × 5), mitoxantrone (12 mg/m2/day × 3), and etoposide (150 mg/m2/day × 3). We treated 33 patients and 17 (51.5%) achieved CR with a median duration of 117 days. Median overall survival was 219 days. Our results suggest that continuous infusion intermediate-dose cytarabine, together with mitoxantrone and etoposide, may induce CR in a significant proportion of patients with refractory or early relapsed AML, although remission duration was short.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Young-Shin Lee, Miee Seol, Seong-Gil Ryu, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi, Jung-Shin Lee, Woo-Kun Kim, Kyoo-Hyung Lee,